+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Factors Influencing the Growth Hormone Response to Growth Hormone-Releasing Hormone in Children with Idiopathic Growth Hormone Deficiency

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Objective: To evaluate the factors influencing the growth hormone (GH) response to GH-releasing hormone (GHRH) test in idiopathic GH deficiency. Methods: 28 patients aged 4.9 ± 0.7 years with certain GH deficiency were given GHRH (2 µg/kg). Results: The GH peak after GHRH was correlated negatively with age at evaluation (r = –0.37, p < 0.05) and body mass index (r = –0.44, p = 0.02), and positively with anterior pituitary height (r = 0.47, p = 0.02), GH peak after non-GHRH stimulation (r = 0.78, p < 0.0001) and spontaneous GH peak (r = 0.82, p = 0.007). It was lower in the patients aged >5 years than in the youngest (p = 0.04), but it was similar in the patients with and without features suggesting a hypothalamic origin. Conclusion: The GH response to GHRH test cannot be used to differentiate between hypothalamic and pituitary forms of idiopathic GH deficiency, probably because the GH response decreases after the first 5 years of life, whatever the origin of the deficiency.

          Related collections

          Most cited references 4

          • Record: found
          • Abstract: not found
          • Article: not found

          Comparison between Insulin-Induced Hypoglycemia and Growth Hormone (GH)-Releasing Hormone + Arginine as Provocative Tests for the Diagnosis of GH Deficiency in Adults

           G Aimaretti (1998)
            • Record: found
            • Abstract: not found
            • Article: not found

            Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection

             M. Pombo (1995)
              • Record: found
              • Abstract: found
              • Article: not found

              Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia.

              Fanconi's anemia can be associated with growth retardation. We describe biologic growth hormone deficiency, isolated or associated with thyrotropin abnormality, and pituitary stalk interruption syndrome on magnetic resonance imaging of 5 patients with Fanconi's anemia. Growth hormone treatment produced catch-up growth in all cases. These findings suggest a common genetic origin.

                Author and article information

                Horm Res Paediatr
                Hormone Research in Paediatrics
                S. Karger AG
                23 August 2002
                : 58
                : 2
                : 94-98
                aPediatric Endocrinology Department and bPhysiology Laboratory, Université René-Descartes and Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, France
                64660 Horm Res 2002;58:94–98
                © 2002 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 1, Tables: 1, References: 19, Pages: 5
                Original Paper


                Comment on this article